Armata Pharmaceuticals, Inc. · AMEX:ARMP
Armata Pharmaceuticals — AmpliPhi Biosciences — Investor Presentation (June 2017)
23 slides from Armata Pharmaceuticals's investor presentation, Jun 6, 2017
Slide 1: Developing Bacteriophage Therapies for Patients with Antibiotic-Resistant Infections
Developing Bacteriophage Therapies for Patients with Antibiotic - Resistant Infections June 6, 2017 NYSE MKT: APHB
Slide 2: Forward-looking statements
2 This presentation contains “forward - looking” statements that involve risks, uncertainties and assumptions. If the risks or uncer tainties materialize or the assumptions prove incorrect, our results may differ materially from those expressed or implied by such for war d - looking statements. All
Slide 3: AmpliPhi Biosciences Overview
3 Antibiotic resistance is a major global health threat AmpliPhi is developing therapies to treat multidrug - resistant (MDR) infections • Bacteriophages can precisely target bacteria, have a differentiated mechanism of action and are potentially synergistic with antibiotics • 10+ years of bacteriop
Slide 4: The world is headed for a post-antibiotic era
4 “ The world is headed for a post - antibiotic era, in which common infections and minor injuries which have been treatable for decades can once again kill .” Dr. Keiji Fukuda, WHO’s Assistant Director - General for Health Security, 2014
Slide 5: Year 2050 Looming Era of Drug-Resistant Superbugs
Year 2050 Looming Era of Drug - Resistant Superbugs 5 Est. $100 trillion worldwide cumulative cost Imagine the world without effective antibiotics - if we fail to act, this could become our reality Est. 10,000,000 annual deaths worldwide Source: 2016 O’Neill Report to UK Government
Slide 6: Resistant Bacterial Infections Responsible for Over 20,000 Deaths per Year in U.S.
6 Resistant Bacterial Infections Responsible for Over 20,000 Deaths per Year in U.S. Alone Source: Pharmacy & Therapeutics 2015; CDC 2014 (*) Community associated U.S. incidence of resistant hospital associated infections Annual deaths attributed to resistant infections Invasive methicillin - resist
Slide 7: The Story of Mr. P: Patient with Deadly Infection
The Story of Mr. P: Patient with Deadly Infection • 68 - year - old male • Contracted abdominal MDR Acinetobacter baumannii infection while traveling • Received multiple courses of antibiotics over 4 - month period • Vancomycin, meropenem , colistin , tigecycline , azithromycin, and rifampin • Criti
Slide 8: The Story of Mr. P: Preparing Personalized Phage Therapy
The Story of Mr. P: Preparing Personalized Phage Therapy • Multi - disciplinary team including UCSD, Texas A&M, SDSU, U.S. Navy, and AmpliPhi • Bacterial isolates screened against phage library • Personalized phage formulations provided within 10 days • Phage administered IP and IV, under Emergency
Slide 9: The Story of Mr. P: Successful Outcome
The Story of Mr. P: Successful Outcome • Patient emerged from coma 4 days after initial phage administration • 5 days after initial phage dose, bacteria became sensitive to antibiotics • Continued phage administration (for selective pressure) and antibiotics • Patient experienced durable microbiolog
Slide 10: Presentation at Scientific Conference
Presentation at Scientific Conference “Intravenous applications of phage therapy to treat a terminally ill patient who was infected with a multidrug - resistant A. baumannii ” by Dr. Biswajit Biswas of the U.S. Navy’s Medical Research Center - Fredrick at Centennial Celebration of Bacteriophage Rese
Slide 11: The Power of Bacteriophages as Targeted Antibacterials
The Power of Bacteriophages as Targeted Antibacterials Harnessing ancient predator - prey relationship to kill bacteria • Naturally occurring viruses • infect and kill only specific bacterial strains • penetrate biofilms Phages are the most abundant and diverse organisms on Earth • Humans evolved wi
Slide 12: How Phage Destroy Bacteria
How Phage Destroy Bacteria Bacteriophage encounters target bacterial cell Bacteriophage binds to target bacteria and injects DNA Bacteriophage converts cell into bacteriophage “factory” Bacteria is lysed, releasing new generation bacteriophages Process repeats as new bacteriophages encounter target
Slide 13: Phage Therapy Has Potential to Reinvigorate Antibiotic Efficacy
13 Patent protection ▪ Protection for sequential administration of phage and antibiotics ▪ Prosecuting both biofilm - dependent and independent induced sensitivity ▪ Broad species coverage in EU, Australia, Japan, Canada; U.S. protection for Pseudomonas Phages can exert selection pressure on MDR bac
Slide 14: Development Pipeline
Development Pipeline Indication Collaborator Discovery Preclinical Phase 1 Phase 2 AB - SA01 (3 - Phage cocktail targeting Staphylococcus aureus ) Chronic Rhinosinusitis (CRS) Seek partner for Phase 2 Topical indications / wound care AB - PA01 (4 - Phage cocktail targeting Pseudomonas aeruginosa ) C
Slide 15: AB-SA01 Completed Phase 1 Trial in Chronic Rhinosinusitis
15 University of Adelaide Patient 1 2 3 4 5 6 7 8 9 10 11 12 13 14 Days AB - SA01 Completed Phase 1 Trial in Chronic Rhinosinusitis Low Dose BID (10 8 PFU/mL) High Dose BID (10 9 PFU/mL) Primary Endpoints ▪ Well tolerated, no drug - related SAEs Secondary Observations ▪ Reduction in S. aureus bacter
Slide 16: AB-SA01 Completed Topical Phase 1 Trial
16 U.S. Army under CRADA Primary Endpoints (all subjects) • AB - SA01 well tolerated throughout the trial ▪ No treatment - emergent AEs considered definitely or probably related to AB - SA01 ▪ No severe or high - grade treatment - emergent AEs ▪ No discontinuation of treatment due to treatment - eme
Slide 17: Positive FDA Feedback at Type B Meeting in February 2017
Positive FDA Feedback at Type B Meeting in February 2017 FDA expressed support for precision phage therapy for patients with serious or life - threatening infections • “CBER acknowledged that phage therapy is an exciting approach to treatment of multidrug - resistant organisms and expressed a commit
Slide 18: Personalized Precision Therapies for MDR Infections
• Provide personalized precisely targeted phage therapies for patients with antibiotic - resistant infections under compassionate use • Serve patients who have few or no other therapeutic options • Demonstrate real - world clinical evidence • Optimize treatment regimens and expand therapeutic phage
Slide 19: Personalized Therapy Operating Model
19 Personalized Therapy Operating Model Nationwide network • Identify patients • Provide treatment Collect data Optimize regimen AmpliPhi Estimates • < 7 - day turnaround for common pathogens • < 14 days for first encounter with new pathogen • On - going pathogen surveillance National Advisory Counc
Slide 20: Regulatory Strategy: Leverage Compassionate-use Clinical Data
20 • Seek partners and grant funding for AB - PA01 CF and AB - SA01 CRS • Focus on compassionate - use strategy to demonstrate clinical efficacy • Treat at least 10 patients in 2017, suffering from high unmet need, serious or life - threatening MDR infections (e.g., endocarditis, PJI, CF, cUTI ) • S
Slide 21: Funding and Capitalization
21 • In May 2017, the Company completed an underwritten offering of common stock and warrants for approximately $9.1M of net proceeds • After considering the recent fundraise, the Company expects existing cash resources to be sufficient to fund operations through mid - 2018 • In addition, the Compan
Slide 22: Management and Board of Directors
Management Paul Grint, M.D. Chief Executive Officer Igor Bilinsky, Ph.D. Chief Operating Officer Steve Martin Chief Financial Officer Alex Gaidamaka, Ph.D., D.V.M. VP CMC Sandra Morales, Ph.D. VP Research Carrie Langlais Furr , Ph.D. VP Regulatory & Project Management 22 Board of Directors Jeremy Cu
Slide 23: Antibiotic resistance is a major global health threat
23 Antibiotic resistance is a major global health threat AmpliPhi is developing therapies to treat MDR infections • Bacteriophages can precisely target bacteria, have a differentiated mechanism of action and are potentially synergistic with antibiotics • 10+ years of bacteriophage R&D, with $60M+ in
AmpliPhi Biosciences — Investor Presentation (June 2017) on 6ix